Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review

1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407. doi: 10.1016/j.ajog.2004.04.025 15343213

2. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol. 2003;188(4):1039–45. 12712107

3. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):51 e1–8.

4. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol. 2005;193(3 Pt 1):771–7.

5. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113(5):559–68. doi: 10.1111/j.1471-0528.2006.00927.x 16637899

6. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol. 2008;64(11):1125–32. doi: 10.1007/s00228-008-0546-y 18685836

7. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sorensen HT. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol. 1999;55(2):139–44. 10335909

8. Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65. doi: 10.3389/fphar.2014.00065 24772083

9. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33(5):328–43. doi: 10.2165/00003088-199733050-00002 9391746

10. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989–1008. doi: 10.2165/00003088-200544100-00001 16176115

11. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2(6):947–60. doi: 10.1517/17425255.2.6.947 17125410

12. DeVane CL, Stowe ZN, Donovan JL, Newport DJ, Pennell PB, Ritchie JC, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20(4 Suppl):54–9. doi: 10.1177/1359786806066054 16785271

13. Leppik IE, Rask CA. Pharmacokinetics of antiepileptic drugs during pregnancy. Semin Neurol. 1988;8(3):240–6. doi: 10.1055/s-2008-1041385 3057557

14. McAuley JW, Anderson GD. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet. 2002;41(8):559–79. doi: 10.2165/00003088-200241080-00002 12102641

15. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology. 2003;61(6 Suppl 2):S35–42.

16. Tomson T, Palm R, Kallen K, Ben-Menachem E, Soderfeldt B, Danielsson B, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111–6. doi: 10.1111/j.1528-1167.2007.01032.x 17381438

17. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62(4):400–7. doi: 10.1016/S0009-9236(97)90118-1 9357391

18. Tsutsumi K, Kotegawa T, Matsuki S, Tanaka Y, Ishii Y, Kodama Y, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther. 2001;70(2):121–5. doi: 10.1067/mcp.2001.116495 11503005

19. Koren G. Pharmacokinetics in pregnancy; clinical significance. J Popul Ther Clin Pharmacol. 2011;18(3):e523–7. 22113390

20. Anger GJ, Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther. 2008;83(1):184–7. doi: 10.1038/sj.clpt.6100377 17882157

21. Dickmann LJ, Isoherranen N. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug Metab Dispos. 2013;41(2):270–4. doi: 10.1124/dmd.112.047118 22815312

22. Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013;41(2):263–9. doi: 10.1124/dmd.112.046276 22837389

23. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2014;77(3):554–70. doi: 10.1111/bcp.12207 23834474

24. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia. 1994;35(1):131–5. 8112235

25. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol. 2003;59(7):553–7. doi: 10.1007/s00228-003-0651-x 12955370

26. Lee JK, Chung HJ, Fischer L, Fischer J, Gonzalez FJ, Jeong H. Human placental lactogen induces CYP2E1 expression via PI 3-kinase pathway in female human hepatocytes. Drug Metab Dispos. 2014;42(4):492–9. doi: 10.1124/dmd.113.055384 24408518

27. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, et al. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015;16(3):176–83. doi: 10.1111/hiv.12195 25407158

28. Chen H, Yang K, Choi S, Fischer JH, Jeong H. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009;37(9):1841–7. doi: 10.1124/dmd.109.026609 19546240

29. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008;66(2):179–95. doi: 10.1111/j.1365-2125.2008.03220.x 18537960

30. Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia. 2008;49(Suppl 9):43–55. doi: 10.1111/j.1528-1167.2008.01926.x 19087117

31. Anderson GD, Carr DB. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin Pharmacokinet. 2009;48(3):159–68. doi: 10.2165/00003088-200948030-00002 19385709

32. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170(11):1240–7. doi: 10.1176/appi.ajp.2013.13010006 24185239

33. Klieger C, Pollex E, Kazmin A, Koren G. Hypoglycemics: pharmacokinetic considerations during pregnancy. Ther Drug Monit. 2009;31(5):533–41. doi: 10.1097/FTD.0b013e3181b385ba 19730277

34. Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014;34(2):244–55. doi: 10.1097/JCP.0000000000000087 24525634

35. McCormack SA, Best BM. Obstetric pharmacokinetic dosing studies are urgently needed. Front Pediatr. 2014;2:9. doi: 10.3389/fped.2014.00009 24575394

36. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 19621072

37. Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK Statement. Clin Pharmacokinet. 2015;54(7):783–95. doi: 10.1007/s40262-015-0236-8 25637173

38. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women? Antimicrob Agents Chemother. 2004;48(2):430–6. doi: 10.1128/AAC.48.2.430-436.2004 14742191

39. Allegaert K, Van Mieghem T, Verbesselt R, Vanhole C, Devlieger R, Cossey V, et al. Cefazolin plasma protein binding saturability during pregnancy. Methods Find Exp Clin Pharmacol. 2009;31(1):25–8. doi: 10.1358/mf.2009.31.1.1338413 19357795

40. Aquirre C, Rodriguez-Sasiain JM, Navajas P, Calvo R. Plasma protein binding of penbutolol in pregnancy. Eur J Drug Metab Pharmacokinet. 1988;13(1):23–6. 3396610

41. Beigi RH, Han K, Venkataramanan R, Hankins GD, Clark S, Hebert MF, et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol. 2011;204(6 Suppl):S84–8. doi: 10.1016/j.ajog.2011.03.002 21492826

42. Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008;9(2):115–25. doi: 10.1310/hct0902-115 18474496

43. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T, et al. Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007;81(4):547–56. doi: 10.1038/sj.clpt.6100126 17329990

44. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502–11. doi: 10.1111/hiv.12252 25959631

45. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquire Immune Defic Syndr. 2010;54(4):381–8.

46. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181(5 Pt 1):1113–7.

47. Fischer JH, Sarto GE, Habibi M, Kilpatrick SJ, Tuomala RE, Shier JM, et al. Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. Antimicrob Agents Chemother. 2012;56(2):715–24. doi: 10.1128/AAC.00717-11 22106226

48. Herngren L, Ehrnebo M, Boreus LO. Drug binding to plasma proteins during human pregnancy and in the perinatal period. Studies on cloxacillin and alprenolol. Dev Pharmacol Ther. 1983;6(2):110–24. 6861596

49. Beaulac-Baillargeon L, Rocheleau S. Paracetamol pharmacokinetics during the first trimester. Eur J Clin Pharmacol. 1994;46(5):451–4. 7957542

50. Matok I, Clark S, Caritis S, Miodovnik M, Umans J, Hankins G, et al. Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. J Clin Pharmacol. 2013;53(3):334–8. doi: 10.1177/0091270012445207 23444286

51. Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, Baiwog F, et al. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob Agents Chemother. 2010;54(1):360–6. doi: 10.1128/AAC.00771-09 19858250

52. Papantoniou N, Ismailos G, Daskalakis G, Karabinas C, Mesogitis S, Papapanagiotou A, et al. Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution. Fetal Diagn Ther. 2007;22(2):100–6. doi: 10.1159/000097105 17135753

53. Popovic J, Grujic Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. J Clin Pharm Ther. 2007;32(6):595–602. doi: 10.1111/j.1365-2710.2007.00864.x 18021337

54. Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987;12(2):136–44. doi: 10.2165/00003088-198712020-00004 3829560

55. Gonik B, Feldman S, Pickering LK, Doughtie CG. Pharmacokinetics of cefoperazone in the parturient. Antimicrob Agents Chemother. 1986;30(6):874–6. 3813513

56. Nathorst-Boos J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. Am J Obstet Gynecol. 1995;172(1):163–6. 7847529

57. Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol. 1982;142(7):823–8. 7065060

58. Herngren L, Ehrnebo M, Boreus LO. Drug distribution in whole blood of mothers and their newborn infants: studies of cloxacillin and flucloxacillin. Eur J Clin Pharmacol. 1982;22(4):351–8. 7106171

59. Heikkila A, Renkonen OV, Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother. 1992;36(12):2652–5. 1482132

60. Heikkila A, Pyykko K, Erkkola R, Iisalo E. The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. Br J Clin Pharmacol. 1992;33(6):629–33. 1389936

61. Nemutlu E, Kir S, Eroglu H, Katlan D, Ozek A, Ozyuncu O, et al. Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. Comb Chem High Throughput Screen. 2010;13(6):502–9. 20426751

62. Heikkila AM, Erkkola RU. The need for adjustment of dosage regimen of penicillin V during pregnancy. Obstet Gynecol. 1993;81(6):919–21. 8497356

63. Heikkila A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother. 1991;28(3):419–23. 1960122

64. Bourget P, Sertin A, Lesne-Hulin A, Fernandez H, Ville Y, Van Peborgh P. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination. Eur J Obstet Gynecol Reprod Biol. 1998;76(1):21–7. 9481541

65. Voigt R, Schroder S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemotherapy. 1985;31(6):417–24. 3908007

66. Peiker G, Traeger A, Pischke U, Schroder S, Muller B, Noschel H. [Studies on the pharmacokinetics of the compound preparation sulfamerazine/trimethoprim (Berlocombin-200) in pregnancy]. Pharmazie. 1982;37(8):578–83. 7146066

67. Voigt R, Schroder S, Meinhold P, Zenner I, Noschel H. [Clinical studies on the effect of pregnancy and labor on the pharmacokinetics of ampicillin]. Zentralbl Gynakol. 1978;100(11):701–5. 356490

68. Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am J Obstet Gynecol. 1993;168(2):667–73. 8438948

69. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72(2):184–91. doi: 10.1067/mcp.2002.126181 12189365

70. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008;69(4):652–8. 18426260

71. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73(4):330–7. 12709723

72. Brogtrop J, Zwarts P, Holleboom CAG, Van Der Linden PD, Touw DJ. [Optimisation of pharmacotherapy for depression during pregnancy. Pilot study for evaluation of existing paroxetine therapy]. Pharmaceutisch Weekblad. 2007;142(11):34–7.

73. Ter Horst PGJ, Larmene-Beld KHM, Bosman J, Van Der Veen EL, Wieringa A, Smit JP. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. J Clin Pharm Ther. 2014;39(5):541–4. doi: 10.1111/jcpt.12188 24989434

74. Rey E, d’Athis P, Giraux P, de Lauture D, Turquais JM, Chavinie J, et al. Pharmacokinetics of clorazepate in pregnant and non-pregnant women. Eur J Clin Pharmacol. 1979;15(3):175–80. 37089

75. Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, Rutherford T, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84(2):248–53. doi: 10.1038/clpt.2008.1 18288078

76. Wilson CM, Dundee JW, Moore J, Howard PJ, Collier PS. A comparison of the early pharmacokinetics of midazolam in pregnant and nonpregnant women. Anaesthesia. 1987;42(10):1057–62. 3688386

77. Battino D, Binelli S, Bossi L, Canger R, Croci D, Cusi C, et al. Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery. Clin Pharmacokinet. 1985;10(3):279–84. doi: 10.2165/00003088-198510030-00007 4017398

78. Bernus I, Hooper WD, Dickinson RG, Eadie MJ. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. Epilepsy Res. 1995;21(1):65–75. 7641678

79. Johnson EL, Stowe ZN, Ritchie JC, Newport DJ, Newman ML, Knight B, et al. Carbamazepine clearance and seizure stability during pregnancy. Epilepsy Behav. 2014;33:49–53. doi: 10.1016/j.yebeh.2014.02.011 24632353

80. Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit. 1985;7(3):269–73. 4049462

81. Yerby MS, Friel PN, McCormick K, Koerner M, Van Allen M, Leavitt AM, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res. 1990;5(3):223–8. 2384078

82. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia. 1994;35(1):122–30. 8112234

83. Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013;29(1):13–8. doi: 10.1016/j.yebeh.2013.06.026 23911354

84. Bernus I, Hooper WD, Dickinson RG, Eadie MJ. Effects of pregnancy on various pathways of human antiepileptic drug metabolism. Clin Neuropharmacol. 1997;20(1):13–21. 9037569

85. Kuhnz W, Steldinger R, Nau H. Protein binding of carbamazepine and its epoxide in maternal and fetal plasma at delivery: comparison to other anticonvulsants. Dev Pharmacol Ther. 1984;7(1):61–72. 6697871

86. Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004;62(2):292–5. 14745072

87. Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70(22 Pt 2):2130–6.

88. de Haan GJ, Edelbroek P, Segers J, Engelsman M, Lindhout D, Devile-Notschaele M, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology. 2004;63(3):571–3. 15304599

89. Fotopoulou C, Kretz R, Bauer S, Schefold JC, Schmitz B, Dudenhausen JW, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85(1):60–4. doi: 10.1016/j.eplepsyres.2009.02.011 19272754

90. Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia. 2008;49(6):1075–80. doi: 10.1111/j.1528-1167.2007.01471.x 18076642

91. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005;65(3):185–8. doi: 10.1016/j.eplepsyres.2005.06.004 16084694

92. Polepally AR, Pennell PB, Brundage RC, Stowe ZN, Newport DJ, Viguera AC, et al. Model-based lamotrigine clearance changes during pregnancy: clinical implication. Ann Clin Transl Neurol. 2014;1(2):99–106. doi: 10.1002/acn3.29 24883336

93. Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology. 2002;59(2):251–5. 12136066

94. Lopez-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav. 2009;15(3):372–5. doi: 10.1016/j.yebeh.2009.04.006 19362602

95. Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure. 2008;17(2):192–8. doi: 10.1016/j.seizure.2007.11.027 18180176

96. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology. 2006;67(8):1497–9. doi: 10.1212/01.wnl.0000240047.11166.0e 17060586

97. Petrenaite V, Sabers A, Hansen-Schwartz J. Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Res. 2009;84(2–3):245–9. doi: 10.1016/j.eplepsyres.2009.01.011 19231139

98. Mazzucchelli I, Onat FY, Ozkara C, Atakli D, Specchio LM, Neve AL, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia. 2006;47(3):504–9. doi: 10.1111/j.1528-1167.2006.00459.x 16529613

99. Appleton MP, Kuehl TJ, Raebel MA, Adams HR, Knight AB, Gold WR. Magnesium sulfate versus phenytoin for seizure prophylaxis in pregnancy-induced hypertension. Am J Obstet Gynecol. 1991;165(4 Pt 1):907–13.

100. Ohman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Research. 2009;87(2–3):124–9. doi: 10.1016/j.eplepsyres.2009.08.004 19740626

101. Westin AA, Nakken KO, Johannessen SI, Reimers A, Lillestolen KM, Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia. 2009;50(3):480–5. doi: 10.1111/j.1528-1167.2008.01776.x 19178558

102. Kulo A, van Calsteren K, Verbesselt R, Smits A, Devlieger R, de Hoon J, et al. The impact of caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. J Biomed Biotechnol. 2012;2012:437639. doi: 10.1155/2012/437639 22675252

103. Gerdin E, Salmonson T, Lindberg B, Rane A. Maternal kinetics of morphine during labour. J Perinat Med. 1990;18(6):479–87. 2097341

104. Rayburn W, Shukla U, Stetson P, Piehl E. Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women. Am J Obstet Gynecol. 1986;155(6):1353–6. 3789044

105. Miners JO, Robson RA, Birkett DJ. Paracetamol metabolism in pregnancy. Br J Clin Pharmacol. 1986;22(3):359–62. 3768250

106. Kulo A, Peeters MY, Allegaert K, Smits A, de Hoon J, Verbesselt R, et al. Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. Br J Clin Pharmacol. 2013;75(3):850–60. doi: 10.1111/j.1365-2125.2012.04402.x 22845052

107. Allegaert K, Peeters MY, Beleyn B, Smits A, Kulo A, van Calsteren K, et al. Paracetamol pharmacokinetics and metabolism in young women. BMC Anesthesiol. 2015;15:163. doi: 10.1186/s12871-015-0144-3 26566962

108. Gin T, Yau G, Jong W, Tan P, Leung RK, Chan K. Disposition of propofol at caesarean section and in the postpartum period. Br J Anaesth. 1991;67(1):49–53. 1859759

109. Gin T, Gregory MA, Chan K, Buckley T, Oh TE. Pharmacokinetics of propofol in women undergoing elective caesarean section. Br J Anaesth. 1990;64(2):148–53. 2138487

110. Cortambert F, Marti-Flich J, Dasset MP, Mullet C. [The pharmacokinetics of propofol used in cesarean section; a preliminary study in the newborn infant]. Cah Anesthesiol. 1989;37(1):33–7. 2784338

111. Chiba K, Ishizaki T, Tabuchi T, Wagatsuma T, Nakazawa Y. Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. Obstet Gynecol. 1982;60(5):620–6. 6815599

112. Rymark P, Berntorp E, Nordsjo P, Liedholm H, Melander A, Gennser G. Low-dose aspirin to pregnant women: single dose pharmacokinetics and influence of short term treatment on bleeding time. J Perinat Med. 1994;22(3):205–11. 7823260

113. Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol. 1995;173(4):1240–5. 7485329

114. Ensom MHH, Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig. 2004;11(6):377–83. doi: 10.1016/j.jsgi.2004.02.007 15350250

115. Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol. 2003;101(6):1307–11. 12798541

116. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191(3):1024–9. doi: 10.1016/j.ajog.2004.05.050 15467584

117. Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A, et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther. 2008;84(3):370–7. doi: 10.1038/clpt.2008.73 18431408

118. Hebert MF, Carr DB, Anderson GD, Blough D, Green GE, Brateng DA, et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol. 2005;45(1):25–33. doi: 10.1177/0091270004269704 15601802

119. Hurst AK, Shotan A, Hoffman K, Johnson J, Goodwin TM, Koda R, et al. Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. Pharmacotherapy. 1998;18(4):840–6. 9692658

120. Buchanan ML, Easterling TR, Carr DB, Shen DD, Risler LJ, Nelson WL, et al. Short communication clonidine pharmacokinetics in pregnancy. Drug Metab Dispos. 2009;37(4):702–5. doi: 10.1124/dmd.108.024984 19116263

121. Hildebrandt R, Weitzel H, Warnke K, Gundert-Remy U. Pharmacokinetics of fenoterol in pregnant and nonpregnant women. Eur J Clin Pharmacol. 1993;45(3):275–7. 8276054

122. Peiker G, Traeger A, Stiller K, Muller B. [Pharmacokinetics and electrolyte balance following administration of furosemide in pregnant women with E gestosis]. Pharmazie. 1984;39(5):336–9. 6473496

123. Fischer JH, Sarto GE, Hardman J, Endres L, Jenkins TM, Kilpatrick SJ, et al. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet. 2014;53(4):373–83. doi: 10.1007/s40262-013-0123-0 24297680

124. Rubin PC, Butters L, Kelman AW, Fitzsimons C, Reid JL. Labetalol disposition and concentration-effect relationships during pregnancy. Br J Clin Pharmacol. 1983;15(4):465–70. 6849783

125. Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1990;162(2):362–6. 2309815

126. Gonser M, Stoll P, Kahle P. Clearance prediction and drug dosage in pregnancy: a clinical study on metildigoxin, and application to other drugs with predominant penal elimination. Clin Drug Investig. 1995;9(4):197–205.

127. Hogstedt S, Rane A. Plasma concentration-effect relationship of metoprolol during and after pregnancy. Eur J Clin Pharmacol. 1993;44(3):243–6. 8491238

128. Prevost RR, Akl SA, Whybrew WD, Sibai BM. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy. 1992;12(3):174–7. 1608848

129. O’Hare MF, Leahey W, Murnaghan GA, McDevitt DG. Pharmacokinetics of sotalol during pregnancy. Eur J Clin Pharmacol. 1983;24(4):521–4. 6861867

130. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006;20(4):553–60. doi: 10.1097/01.aids.0000210609.52836.d1 16470119

131. Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med. 2011;12(9):570–9. doi: 10.1111/j.1468-1293.2011.00927.x 21569187

132. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007;21(18):2409–15. doi: 10.1097/QAD.0b013e32825a69d1 18025877

133. Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquire Immune Defic Syndr. 2013;63(1):59–66.

134. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquire Immune Defic Syndr. 2011;56(5):412–9.

135. Else LJ, Jackson V, Brennan M, Back DJ, Khoo SH, Coulter-Smith S, et al. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV Med. 2014;15(10):604–10. doi: 10.1111/hiv.12164 24825070

136. Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Gingelmaier A, Weizsacker K, et al. Atazanavir exposure is effective during pregnancy regardless of tenofovir use. Antivir Ther. 2015;20(1):57–64. doi: 10.3851/IMP2820 24992294

137. Le MP, Mandelbrot L, Descamps D, Soulie C, Ichou H, Bourgeois-Moine A, et al. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women. Antivir Ther. 2015;20(5):507–13. doi: 10.3851/IMP2936 25599649

138. Colbers A, Molto J, Ivanovic J, Kabeya K, Hawkins D, Gingelmaier A, et al. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. J Antimicrob Chemother. 2015;70(2):534–42. doi: 10.1093/jac/dku400 25326090

139. Zorrilla CD, Wright R, Osiyemi O, Yasin S, Baugh B, Brown K, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100mg administered twice daily. HIV Med. 2014;15(1):50–6. doi: 10.1111/hiv.12047 23731450

140. Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, et al. Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women. J Acquire Immune Defic Syndr. 2015;70(1):33–41.

141. Wang Y, Livingston E, Patil S, McKinney RE, Bardeguez AD, Gandia J, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus—infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis. 1999;180(5):1536–41. doi: 10.1086/315067 10515813

142. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, et al. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014;54(2):121–32. doi: 10.1002/jcph.167 24038035

143. Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquire Immune Defic Syndr. 2012;59(3):245–52.

144. Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, et al. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin Pharmacol Ther. 2015;97(3):298–306. doi: 10.1002/cpt.43 25669165

145. Colbers APH, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27(5):739–48. doi: 10.1097/QAD.0b013e32835c208b 23169329

146. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012;13(4):226–35. doi: 10.1111/j.1468-1293.2011.00965.x 22129166

147. Valade E, Treluyer JM, Dabis F, Arrive E, Pannier E, Benaboud S, et al. Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. Br J Clin Pharmacol. 2014;78(6):1378–86. doi: 10.1111/bcp.12457 24995851

148. Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, et al. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol. 2013;76(3):475–83. doi: 10.1111/bcp.12078 23305215

149. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003;17(8):1195–9. doi: 10.1097/01.aids.0000060367.78202.cb 12819521

150. Unadkat JD, Wara DW, Hughes MD, Mathias AA, Holland DT, Paul ME, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51(2):783–6. doi: 10.1128/AAC.00420-06 17158945

151. Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56(2):776–82. doi: 10.1128/AAC.00370-11 22106227

152. Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother. 2009;63(6):1223–32. doi: 10.1093/jac/dkp123 19389715

153. Calza L, Manfredi R, Trapani F, Salvadori C, Colangeli V, Borderi M, et al. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. Scand J Infect Dis. 2012;44(5):381–7. doi: 10.3109/00365548.2011.642306 22263609

154. Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother. 2012;56(2):816–24. doi: 10.1128/AAC.05186-11 22106215

155. Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 2011;12(3):166–73. doi: 10.1111/j.1468-1293.2010.00865.x 20726906

156. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquire Immune Defic Syndr. 2008;49(5):485–91.

157. Ramautarsing RA, Van Der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS. 2011;25(10):1299–303. doi: 10.1097/QAD.0b013e328347f7e9 21516029

158. Santini-Oliveira M, Estrela Rde C, Veloso VG, Cattani VB, Yanavich C, Velasque L, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother. 2014;58(5):2884–93. doi: 10.1128/AAC.02599-13 24614377

159. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20(15):1931–9. doi: 10.1097/01.aids.0000247114.43714.90 16988514

160. Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, et al. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquire Immune Defic Syndr. 2013;63(1):51–8.

161. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010;11(4):232–8. doi: 10.1111/j.1468-1293.2009.00767.x 20002783

162. Fauchet F, Treluyer JM, Illamola SM, Pressiat C, Lui G, Valade E, et al. Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment. Antimicrob Agents Chemother. 2015;59(9):5727–35. doi: 10.1128/AAC.00863-15 26149996

163. Fang A, Valluri SR, O’Sullivan MJ, Maupin R, Jones T, Delke I, et al. Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum. HIV Clin Trials. 2012;13(1):46–59. doi: 10.1310/hct1301-046 22306587

164. Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother. 2006;50(6):2079–86. doi: 10.1128/AAC.01596-05 16723569

165. Nellen JFJB, Schillevoort I, Wit FWNM, Bergshoeff AS, Godfried MH, Boer K, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis. 2004;39(5):736–40. doi: 10.1086/422719 15356791

166. Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, et al. Pharmacokinetics of new 625mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008;9(10):875–82. doi: 10.1111/j.1468-1293.2008.00640.x 18795962

167. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62(3):309–15. doi: 10.1111/j.1365-2125.2006.02669.x 16934047

168. Van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther. 2004;76(6):588–97. doi: 10.1016/j.clpt.2004.08.011 15592330

169. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9(4):214–20. doi: 10.1111/j.1468-1293.2008.00553.x 18366444

170. Nellen JFJB, Damming M, Godfried MH, Boer K, Van Der Ende ME, Burger DM, et al. Steady-state nevirapine plasma concentrations are influenced by pregnancy. HIV Med. 2008;9(4):234–8. doi: 10.1111/j.1468-1293.2008.00551.x 18366447

171. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquire Immune Defic Syndr. 2010;55(3):345–50.

172. Blonk M, Colbers A, Hidalgo-Tenorio C, Weizsacker K, Molto J, Hawkins D, et al. A comparison of the pharmacokinetics of raltegravir during pregnancy and postpartum. Top Antivir Med. 2014;22 (e-1):465.

173. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014;67(4):375–81. doi: 10.1097/QAI.0000000000000318 25162818

174. Martinez-Rebollar M, Lonca M, Perez I, Soy D, Brunet M, Martin R, et al. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. Ther Drug Monit. 2011;33(6):772–7. doi: 10.1097/FTD.0b013e318236376d 22105596

175. van der Lug J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, et al. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009;14(3):443–50. 19474478

176. von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, et al. Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther. 2008;13(8):1039–46. 19195329

177. Cespedes MS, Castor D, Ford SL, Lee D, Lou Y, Pakes GE, et al. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquire Immune Defic Syndr. 2013;62(5):550–4.

178. Green MD, Van Eijk AM, Van Ter Kuile FO, Ayisi JG, Parise ME, Kager PA, et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in western Kenya. J Infect Dis. 2007;196(9):1403–8. doi: 10.1086/522632 17922406

179. Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, et al. Pregnancy-related effects on tenofovir pharmacokinetics: A population study with 186 women. Antimicrob Agents Chemother. 2012;56(2):857–62. doi: 10.1128/AAC.05244-11 22123690

180. Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, Blanche S, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009;85(2):182–9. doi: 10.1038/clpt.2008.201 18987623

181. Mosha D, Guidi M, Mwingira F, Abdulla S, Mercier T, Decosterd LA, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58(8):4583–92. doi: 10.1128/AAC.02595-14 24867986

182. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62(12):1021–31. doi: 10.1007/s00228-006-0199-7 17053895

183. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, Looareesuwan S, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol. 2003;59(7):545–52. doi: 10.1007/s00228-003-0652-9 12955371

184. Chukwuani MC, Bolaji OO, Onyeji CO, Makinde ON, Ogunbona FA. Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy. Trop Med Int Health. 2004;9(5):601–5. doi: 10.1111/j.1365-3156.2004.01227.x 15117305

185. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, et al. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob Agents Chemother. 2010;54(3):1186–92. doi: 10.1128/AAC.01269-09 20086162

186. Lee SJ, McGready R, Fernandez C, Stepniewska K, Paw MK, Viladpai-Nguen SJ, et al. Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol. 2008;64(10):987–92. doi: 10.1007/s00228-008-0500-z 18594802

187. Massele AY, Kilewo C, Aden Abdi Y, Tomson G, Diwan VK, Ericsson O, et al. Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy. Eur J Clin Pharmacol. 1997;52(4):299–305. 9248769

188. Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, et al. Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated plasmodium falciparum malaria in Uganda. CPT Pharmacometrics Syst Pharmacol. 2013;2(11):e83.

189. Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, et al. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. Antimicrob Agents Chemother. 2013;57(10):5096–103. doi: 10.1128/AAC.00683-13 23917320

190. Nosten F, Karbwang J, White NJ, Honeymoon, Na Bangchang K, Bunnag D, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol. 1990;30(1):79–85. 2390434

191. Bangchang KN, Davis TME, Looareesuwan S, White NJ, Bunnag D, Karbwang J. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg. 1994;88(3):321–3. 7974678

192. Valea I, Tinto H, Coulibaly MT, Toe LC, Lindegardh N, Tarning J, et al. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. J Antimicrob Chemother. 2014;69(9):2499–507. doi: 10.1093/jac/dku154 24891429

193. Rijken MJ, McGready R, Phyo AP, Lindegardh N, Tarning J, Laochan N, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2011;55(12):5500–6. doi: 10.1128/AAC.05067-11 21947392

194. Benjamin JM, Moore BR, Salman S, Page-Sharp M, Tawat S, Yadi G, et al. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother. 2015;59(7):4260–71. doi: 10.1128/AAC.00326-15 25963981

195. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NPJ, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56(4):1997–2007. doi: 10.1128/AAC.05756-11 22252822

196. Wangboonskul J, White NJ, Nosten F, Ter Kuile F, Moody RR, Taylor RB. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol. 1993;44(3):247–51. 8491239

197. Onyamboko MA, Meshnick SR, Fleckenstein L, Koch MA, Atibu J, Lokomba V, et al. Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC. Malar J. 2011;10(49).

198. McGready R, Phyo AP, Rijken MJ, Tarning J, Lindegardh N, Hanpithakpon W, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol. 2012;73(3):467–77. doi: 10.1111/j.1365-2125.2011.04103.x 21950338

199. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, et al. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother. 2009;53(10):4368–76. doi: 10.1128/AAC.00335-09 19620325

200. Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, et al. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther. 2010;87(2):226–34. doi: 10.1038/clpt.2009.177 19776738

201. Concheiro M, Jones HE, Johnson RE, Choo R, Huestis MA. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit. 2011;33(5):619–26. doi: 10.1097/FTD.0b013e318228bb2a 21860340

202. Bogen DL, Perel JM, Helsel JC, Hanusa BH, Romkes M, Nukui T, et al. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. Psychopharmacology. 2013;225(2):441–51. doi: 10.1007/s00213-012-2833-7 22926004

203. Jarvis MAE, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis. 1999;18(4):51–61. doi: 10.1300/J069v18n04_05 10631963

204. Wolff K, Boys A, Rostami-Hodjegan A, Hay A, Raistrick D. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol. 2005;61(10):763–8. doi: 10.1007/s00228-005-0035-5 16261362

205. Van Calsteren K, Verbesselt R, Ottevanger N, Halaska M, Heyns L, Van Bree R, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010;89(10):1338–45. doi: 10.3109/00016349.2010.512070 20846067

206. Zemlickis D, Klein J, Moselhy G, Koren G. Cisplatin protein binding in pregnancy and the neonatal period. Med Pediatr Oncol. 1994;23(6):476–9. 7935173

207. Bjorklund AO, Adamson UKC, Lins PES, Westgren LMR. Diminished insulin clearance during late pregnancy in patients with Type I diabetes mellitus. Clin Sci. 1998;95(3):317–23. 9730851

208. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67–72. 16418696

209. Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GDV, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38(5):833–40. doi: 10.1124/dmd.109.031245 20118196

210. Hughes RCE, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23(3):323–6. doi: 10.1111/j.1464-5491.2005.01769.x 16492218

211. Bajoria R, Oteng-Ntim E, Peek MJ, Fisk NM. Pharmacokinetics and pharmacodynamics of TRH during pregnancy. Obstet Gynecol. 1997;90(2):176–82. doi: 10.1016/S0029-7844(97)00221-4 9241288

212. Davison JM, Sheills EA, Philips PR, Barron WM, Lindheimer MD. Metabolic clearance of vasopressin and an analogue resistant to vasopressinase in human pregnancy. Am J Physiol Renal Physiol. 1993;264(2 Pt 2):F348–53.

213. Caritis SN, Venkataramanan R, Cotroneo M, Chiao JP. Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol. 1989;161(1):32–5. 2641984

214. Berg G, Lindberg C, Ryden G. Terbutaline in the treatment of preterm labour. Eur J Respir Dis Suppl. 1984;134:219–30. 6586483

215. ter Laak MA, Roos C, Touw DJ, van Hattum PR, Kwee A, Lotgering FK, et al. Pharmacokinetics of nifedipine slow-release during sustained tocolysis. Int J Clin Pharmacol Ther. 2015;53(1):84–91. doi: 10.5414/CP202215 25407260

216. Ryu RJ, Eyal S, Kaplan HG, Akbarzadeh A, Hays K, Puhl K, et al. Pharmacokinetics of doxorubicin in pregnant women. Cancer Chemother Pharmacol. 2014;73(4):789–97. doi: 10.1007/s00280-014-2406-z 24531558

217. Freeman MP, Nolan PE Jr, Davis MF, Anthony M, Fried K, Fankhauser M, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008;28(6):646–53. doi: 10.1097/JCP.0b013e31818d2048 19011433

218. O’Hare MF, Kinney CD, Murnaghan GA, McDevitt DG. Pharmacokinetics of propranolol during pregnancy. Eur J Clin Pharmacol. 1984;27(5):583–7. 6519163

219. Smith MT, Livingstone I, Eadie MJ, Hooper WD, Triggs EJ. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics. Eur J Clin Pharmacol. 1983;25(4):481–90. 6653642

220. Abdelrahim II, Adam I, Elghazali G, Gustafsson LL, Elbashir MI, Mirghani RA. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. J Clin Pharm Ther. 2007;32(1):15–9. doi: 10.1111/j.1365-2710.2007.00788.x 17286785

221. Shere M, Nguyen P, Tam C, Stern S, Kapur B, O’Connor D, et al. Optimizing periconceptional folic acid supplementation: steady-state folate pharmacokinetics in pregnancy. FASEB J. 2014;28:LB416.

222. Gregory IJF, Caudill MA, Jeffery Opalko F, Bailey LB. Kinetics of folate turnover in pregnant women (second trimester) and nonpregnant controls during folic acid supplementation: stable-isotopic labeling of plasma folate, urinary folate and folate catabolites shows subtle effects of pregnancy on turnover of folate pools. J Nutr. 2001;131(7):1928–37. 11435509

223. Roth DE, Al Mahmud A, Raqib R, Akhtar E, Black RE, Baqui AH. Pharmacokinetics of high-dose weekly oral vitamin D3 supplementation during the third trimester of pregnancy in Dhaka, Bangladesh. Nutrients. 2013;5(3):788–810. doi: 10.3390/nu5030788 23482056

224. Roth DE, Al Mahmud A, Raqib R, Black RE, Baqui AH. Pharmacokinetics of a single oral dose of vitamin D3 (70,000 IU) in pregnant and non-pregnant women. Nutr J. 2012;11:114. doi: 10.1186/1475-2891-11-114 23268736

225. Voigt R, Schroder S, Bierwisch I, Michels W, Spencker FB. [Pharmacokinetic studies of cefotiam in late pregnancy]. Z Geburtshilfe Perinatol. 1989;193(4):185–7. 2800661

226. Peiker G, Muller B, Voigt G, Noschel H. [Blood level kinetics of sodium noramidopyrine methansulphonate (Analgin) in late pregnancy]. Pharmazie. 1983;38(6):406–8. 6611643

227. Guay J, Beaudry B, Lortie L, Varin F. Pharmacokinetics of atracurium in pregnant women. Clin Drug Investig. 1996;11(3):167–73.

228. Pihlajamaki K, Kanto J, Lindberg R, Karanko M, Kiilholma P. Extradural administration of bupivacaine: pharmacokinetics and metabolism in pregnant and non-pregnant women. Br J Anaesth. 1990;64(5):556–62. 2354094

229. Peiker G, Mueller B, Ihn W, Noeschel H. [The pharmacokinetics of pethidin (Dolcontral) of parturients and their new-borns]. Pharmazie. 1981;36(8):560–3. 7291290

230. Elkomy MH, Sultan P, Carvalho B, Peltz G, Wu M, Clavijo C, et al. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. Clin Pharmacol Ther. 2015;97(2):167–76. doi: 10.1002/cpt.5 25670522

231. O’Sullivan MJ, Boyer PJJ, Scott GB, Parks WP, Weller S, Blum R, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol. 1993;168(5):1510–6. 8098905

232. Shi YE, Ye ZH, He CH, Zhang GQ, Xu JQ, Van Look PFA, et al. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception. 1993;48(2):133–49. 8403910

233. Gardner DF, Cruikshank DP, Hays PM, Cooper DS. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests. J Clin Endocrinol Metab. 1986;62(1):217–20. doi: 10.1210/jcem-62-1-217 3940267

234. Chopra IJ, Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy? Metabolism. 2003;52(1):122–8. doi: 10.1053/meta.2003.50019 12524672

235. Ensom MHH, Stephenson MD. A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. Hum Reprod. 2011;26(9):2283–8. doi: 10.1093/humrep/der227 21771770

236. Rijken MJ, McGready R, Jullien V, Tarning J, Lindegardh N, Phyo AP, et al. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob Agents Chemother. 2011;55(9):4338–42. doi: 10.1128/AAC.00154-11 21709098

237. Kloprogge F, Jullien V, Piola P, Dhorda M, Muwanga S, Nosten F, et al. Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. J Antimicrob Chemother. 2014;69(11):3033–40. doi: 10.1093/jac/dku228 24970740

238. Goodwin TM, Millar L, North L, Abrams LS, Weglein RC, Holland ML. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant-women with preterm uterine contractions. Am J Obstet Gynecol. 1995;173(3):913–7. 7573268

239. Leake RD, Weitzman RE, Fisher DA. Pharmacokinetics of oxytocin in the human subject. Obstet Gynecol. 1980;56(6):701–4. 7443113

240. Hutchings MJ, Paull JD, Wilson-Evered E, Morgan DJ. Pharmacokinetics and metabolism of salbutamol in premature labour. Br J Clin Pharmacol. 1987;24(1):69–75. 3620288

241. Peiker G, Muller B, Dawczynski H, Erdmann M, Scharke U. [Comparison of the pharmacokinetics of iron in pregnant and nonpregnant women after oral administration of Vitaferro]. Pharmazie. 1988;43(5):335–6. 3174811

242. Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, Hensleigh PA, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol. 1991;164(2):569–76. 1847004

243. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990–2008. Natl Vital Stat Rep. 2012;60(7):1–21. 22970648

244. Yogev Y, Melamed N, Bardin R, Tenenbaum-Gavish K, Ben-Shitrit G, Ben-Haroush A. Pregnancy outcome at extremely advanced maternal age. Am J Obstet Gynecol. 2010;203(6):558.e1–7.

245. Thorpe PG, Gilboa SM, Hernandez-Diaz S, Lind J, Cragan JD, Briggs G, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf. 2013;22(9):1013–8. doi: 10.1002/pds.3495 23893932

246. McDade TW, Williams S, Snodgrass JJ. What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography. 2007;44(4):899–925. 18232218

247. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263. doi: 10.1186/1475-2875-10-263 21914160

248. Chan WS, Rey E, Kent NE, VTE in Pregnancy Guideline Working Group. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527–53. 24927193